Wes Hinsley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wes Hinsley has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Neil Morris Ferguson
MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK
8 shared publications - Samir Bhatt
Section for Health Data Science and AI, Department of Public Health, University of Copenhagen, Copenhagen, Denmark
6 shared publications - Daniel Joseph Laydon
MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London
5 shared publications - Azra C. Ghani
MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London
3 shared publications - Bimandra Adiputra Djaafara
Oxford University Clinical Research Unit Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
3 shared publications - Katy A. M. Gaythorpe
MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom
3 shared publications
Latest Publications
- Open Access
- 17 March 2026
- Published by Elsevier in SSRN Electronic Journal
Dengue in Sri Lanka: Analysing Spatiotemporal Variations in Transmission Intensity through the Analysis of Case-Notification Data
Background: The recent licensure of the TAK-003 dengue vaccine, and advances in vector management provide new opportunities for dengue control. To evaluate their local impact, it is necessary to characterise dengue virus (DENV) transmission intensity. Age-stratified case-notification data from routine surveillance can help estimate transmission intensity over time and space, revealing hidden infection burden and transmission hotspots, even in areas with unequal surveillance or healthcare access. Methods: We applied time-constant and time-varying catalytic models to age-stratified dengue incidence data (2017-2024) across Sri Lankan districts, to characterise heterogeneities in the Force of Infection (FOI), the per-capita annual risk of infection for a susceptible person. We reconstructed the sensitivity of surveillance by estimating the proportion of infections reported and also explored associations between the FOI and climatic and socioeconomic factors using spatiotemporal regression models within the Integrated Nested Laplace Approximations (INLA) framework. Findings: FOI estimates and reporting rates were highly heterogeneous across the country, with the estimated seroprevalence at age 9 years ranging from 7.9% (95% Credible Interval CrI: 6.0, 10.0%) in Polonnaruwa to 46.4% (95%CrI: 37.1, 55.5%) in Jaffna. In the multivariable analysis no climatic or socioeconomic variable showed a statistically significant association with the dengue yearly average FOI, after adjustment for spatial and temporal random effects. Interpretation: These results suggest that the dengue FOI and the sensitivity of surveillance are highly heterogeneous across Sri Lanka and the introduction of the TAK-003 dengue vaccine needs to be carefully evaluated. Wellcome Trust Grant Number(s): 213494/Z/18/Z, 226072/Z/22/Z, 226727/Z/22/Z and 228185/Z/23/Z Data Availability Statement: The code and the Shinyapp to estimate the dengue FOI are available at https://github.com/mrc-ide/SriLanka_FOI/ together with a simulated dataset of the Sri Lanka number of cases by year, district and age-group. The reported case-notification data collected by the Ministry of Health of Sri Lanka can be accessed upon request. Requests should be addressed to the National Disease Control Unit which can be contacted at ndcu2010@yahoo.com
- 17 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDengue in Sri Lanka: Analysing Spatiotemporal Variations in Transmission Intensity through the Analysis of Case-Notification Data
Background: The recent licensure of the TAK-003 dengue vaccine, and advances in vector management provide new opportunities for dengue control. To evaluate their local impact, it is necessary to characterise dengue virus (DENV) transmission intensity. Age-stratified case-notification data from routine surveillance can help estimate transmission intensity over time and space, revealing hidden infection burden and transmission hotspots, even in areas with unequal surveillance or healthcare access. Methods: We applied time-constant and time-varying catalytic models to age-stratified dengue incidence data (2017-2024) across Sri Lankan districts, to characterise heterogeneities in the Force of Infection (FOI), the per-capita annual risk of infection for a susceptible person. We reconstructed the sensitivity of surveillance by estimating the proportion of infections reported and also explored associations between the FOI and climatic and socioeconomic factors using spatiotemporal regression models within the Integrated Nested Laplace Approximations (INLA) framework. Findings: FOI estimates and reporting rates were highly heterogeneous across the country, with the estimated seroprevalence at age 9 years ranging from 7.9% (95% Credible Interval CrI: 6.0, 10.0%) in Polonnaruwa to 46.4% (95%CrI: 37.1, 55.5%) in Jaffna. In the multivariable analysis no climatic or socioeconomic variable showed a statistically significant association with the dengue yearly average FOI, after adjustment for spatial and temporal random effects. Interpretation: These results suggest that the dengue FOI and the sensitivity of surveillance are highly heterogeneous across Sri Lanka and the introduction of the TAK-003 dengue vaccine needs to be carefully evaluated. Wellcome Trust Grant Number(s): 213494/Z/18/Z, 226072/Z/22/Z, 226727/Z/22/Z and 228185/Z/23/Z Data Availability Statement: The code and the Shinyapp to estimate the dengue FOI are available at https://github.com/mrc-ide/SriLanka_FOI/ together with a simulated dataset of the Sri Lanka number of cases by year, district and age-group. The reported case-notification data collected by the Ministry of Health of Sri Lanka can be accessed upon request. Requests should be addressed to the National Disease Control Unit which can be contacted at ndcu2010@yahoo.com
- Open Access
- 23 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (21) , eadu8678
Socioeconomic and temporal heterogeneity in SARS-CoV-2 exposure and disease in England from May 2020 to February 2023
The impact of COVID-19 varied significantly by deprivation, ethnicity, and policy measures. We analyzed individual-level data on 12,310,485 first SARS-CoV-2 Pillar 2–PCR-confirmed infections, 439,083 hospitalizations, 107,823 deaths, and vaccination records in England from May 2020 to February 2022. Poisson regression models adjusted for demographic and temporal factors showed higher incidence rate ratios (IRRs) for severe outcomes in the most deprived areas compared to the least. We note higher IRRs for severe outcomes for all non-white relative to white ethnicities. The magnitude of IRRs for both deprivation and ethnicities declined from the wild-type to the omicron periods for severe outcomes. For infections, we observed IRRs above one for non-white ethnicities during the wild-type and alpha periods. Vaccination significantly reduced risks across all groups. For severe outcomes, preexisting health inequalities led to large and persistent disparities. For infections, measures must be structured with ethnicity and deprivation in mind early in a pandemic.
- 23 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (21) , eadu8678
Open AccessSocioeconomic and temporal heterogeneity in SARS-CoV-2 exposure and disease in England from May 2020 to February 2023
The impact of COVID-19 varied significantly by deprivation, ethnicity, and policy measures. We analyzed individual-level data on 12,310,485 first SARS-CoV-2 Pillar 2–PCR-confirmed infections, 439,083 hospitalizations, 107,823 deaths, and vaccination records in England from May 2020 to February 2022. Poisson regression models adjusted for demographic and temporal factors showed higher incidence rate ratios (IRRs) for severe outcomes in the most deprived areas compared to the least. We note higher IRRs for severe outcomes for all non-white relative to white ethnicities. The magnitude of IRRs for both deprivation and ethnicities declined from the wild-type to the omicron periods for severe outcomes. For infections, we observed IRRs above one for non-white ethnicities during the wild-type and alpha periods. Vaccination significantly reduced risks across all groups. For severe outcomes, preexisting health inequalities led to large and persistent disparities. For infections, measures must be structured with ethnicity and deprivation in mind early in a pandemic.
- Open Access
Cost-effectiveness of geographically targeted versus ring vaccination campaigns in response to an outbreak of Ebola Virus Disease
For response to an outbreak of Ebola Virus Disease (EVD), the World Health Organisation (WHO) guidelines recommend vaccination of any contacts and contacts-of-contacts of identified EVD cases, also known as ring vaccination. However this standard response can be challenging to implement in remote regions or conflict zones. In recent outbreaks, response efforts have also tried blanket vaccination in the immediate vicinity of the homes and workplaces of identified cases, also known as geographically targeted vaccination. The relative effectiveness of these deployment strategies is difficult to study empirically, and modelling work to date has been limited. In this study, we use a spatially explicit individual-based stochastic simulation to model an EVD epidemic and public health response using either ring or geographically targeted vaccination alongside standard response activities. We explore a wide range of outbreak scenarios and response levels. Overall, we find little difference between ring or geographically targeted vaccination for either health or cost outcomes; the quality of surveillance and effectiveness of standard response activities are much larger drivers. However, vaccination does provide incremental benefit in combination with those activities, and the preferred strategy changes depending how well non-pharmaceutical activities are executed. Ring vaccination provides more incremental benefit on top of otherwise effective response activities (e.g. rapid and high ascertainment of contacts) but geographically targeted vaccination is better when those activities are less effectively delivered. These findings are relevant to policy makers deciding how to most effectively and cost-effectively deploy EVD vaccines in resource-limited and often challenging outbreak settings.
Open AccessCost-effectiveness of geographically targeted versus ring vaccination campaigns in response to an outbreak of Ebola Virus Disease
For response to an outbreak of Ebola Virus Disease (EVD), the World Health Organisation (WHO) guidelines recommend vaccination of any contacts and contacts-of-contacts of identified EVD cases, also known as ring vaccination. However this standard response can be challenging to implement in remote regions or conflict zones. In recent outbreaks, response efforts have also tried blanket vaccination in the immediate vicinity of the homes and workplaces of identified cases, also known as geographically targeted vaccination. The relative effectiveness of these deployment strategies is difficult to study empirically, and modelling work to date has been limited. In this study, we use a spatially explicit individual-based stochastic simulation to model an EVD epidemic and public health response using either ring or geographically targeted vaccination alongside standard response activities. We explore a wide range of outbreak scenarios and response levels. Overall, we find little difference between ring or geographically targeted vaccination for either health or cost outcomes; the quality of surveillance and effectiveness of standard response activities are much larger drivers. However, vaccination does provide incremental benefit in combination with those activities, and the preferred strategy changes depending how well non-pharmaceutical activities are executed. Ring vaccination provides more incremental benefit on top of otherwise effective response activities (e.g. rapid and high ascertainment of contacts) but geographically targeted vaccination is better when those activities are less effectively delivered. These findings are relevant to policy makers deciding how to most effectively and cost-effectively deploy EVD vaccines in resource-limited and often challenging outbreak settings.
- Open Access
Socioeconomic and temporal heterogeneity in SARS-CoV-2 exposure and disease in England from May 2020 to February 2023
The impact of COVID-19 varied significantly by deprivation, ethnicity, and policy measures. We analysed individual-level data on 12,310,485 first SARS-CoV-2 Pillar-2-PCR-confirmed infections, 439,083 hospitalisations, 107,823 deaths, and vaccination records in England from May 2020 to February 2022. Poisson regression models adjusted for demographic and temporal factors showed higher incidence rate ratios (IRRs) for severe outcomes in the most deprived areas compared to the least. We note higher IRRs for severe outcomes for all non-White relative to White ethnicities. The magnitude of IRRs for both deprivation and ethnicities declined from the wild-type to the omicron periods for severe outcomes. For infections, we observed IRRs above one for non-White ethnicities during the wild-type and alpha periods. Vaccination significantly reduced risks across all groups. For severe outcomes, pre-existing health inequalities led to large and persistent disparities. For infections, measures must be structured with ethnicity and deprivation in mind early in a pandemic.
Open AccessSocioeconomic and temporal heterogeneity in SARS-CoV-2 exposure and disease in England from May 2020 to February 2023
The impact of COVID-19 varied significantly by deprivation, ethnicity, and policy measures. We analysed individual-level data on 12,310,485 first SARS-CoV-2 Pillar-2-PCR-confirmed infections, 439,083 hospitalisations, 107,823 deaths, and vaccination records in England from May 2020 to February 2022. Poisson regression models adjusted for demographic and temporal factors showed higher incidence rate ratios (IRRs) for severe outcomes in the most deprived areas compared to the least. We note higher IRRs for severe outcomes for all non-White relative to White ethnicities. The magnitude of IRRs for both deprivation and ethnicities declined from the wild-type to the omicron periods for severe outcomes. For infections, we observed IRRs above one for non-White ethnicities during the wild-type and alpha periods. Vaccination significantly reduced risks across all groups. For severe outcomes, pre-existing health inequalities led to large and persistent disparities. For infections, measures must be structured with ethnicity and deprivation in mind early in a pandemic.
- Open Access
Modelling the impact of vaccination on SARS-CoV-2 transmission in England
While the efficacy of SARS-CoV-2 vaccination against severe disease and mortality is well-established, its impact on population-level transmission remains a critical yet poorly quantified frontier in public health. Previous evidence has largely relied on small-scale cohort or household studies. However, these settings often lack the scale to capture the broader ecological impact of vaccination on epidemic growth, and therefore its implications for epidemic control. Here, we quantify the effectiveness of SARS-CoV-2 vaccination against transmission in England by fitting a Bayesian hierarchical model to estimates of the time-varying effective reproduction number ( R t ) during 2021. Vaccine effectiveness for one, two and three doses was defined as the proportional reduction in R t . The model integrates high-resolution data on vaccination uptake by age group, the shifting landscape of circulating variants, and regional transmission trends across 221 Lower Tier Local Authorities. We find that a first vaccine dose provided moderate-to-large effectiveness against transmission (45.4% (95% CrI: 38.5–51.9%)), whereas the second dose offered negligible additional transmission-blocking effects. A third dose significantly restored effectiveness (66.3% (40.3–90.1%)), albeit with higher uncertainty. Surprisingly, although a link between socio-economic deprivation and transmission is highly plausible, we find that deprivation was not a significant driver of transmission heterogeneity during the vaccination rollout. The model accurately reproduces observed spatial and temporal variation in R t across England. To our knowledge, these findings provide the first population-level evidence that vaccination substantially reduces the SARS-CoV-2 reproduction number, supporting the UK’s “first-doses-first” prioritization as effective tools for epidemic control. More broadly, our modelling framework offers an approach for assessing transmission-blocking effects of vaccines against respiratory pathogens using routinely collected surveillance data, and has implications beyond SARS-CoV-2 for emerging threats such as avian influenza (H5N1).
Open AccessModelling the impact of vaccination on SARS-CoV-2 transmission in England
While the efficacy of SARS-CoV-2 vaccination against severe disease and mortality is well-established, its impact on population-level transmission remains a critical yet poorly quantified frontier in public health. Previous evidence has largely relied on small-scale cohort or household studies. However, these settings often lack the scale to capture the broader ecological impact of vaccination on epidemic growth, and therefore its implications for epidemic control. Here, we quantify the effectiveness of SARS-CoV-2 vaccination against transmission in England by fitting a Bayesian hierarchical model to estimates of the time-varying effective reproduction number ( R t ) during 2021. Vaccine effectiveness for one, two and three doses was defined as the proportional reduction in R t . The model integrates high-resolution data on vaccination uptake by age group, the shifting landscape of circulating variants, and regional transmission trends across 221 Lower Tier Local Authorities. We find that a first vaccine dose provided moderate-to-large effectiveness against transmission (45.4% (95% CrI: 38.5–51.9%)), whereas the second dose offered negligible additional transmission-blocking effects. A third dose significantly restored effectiveness (66.3% (40.3–90.1%)), albeit with higher uncertainty. Surprisingly, although a link between socio-economic deprivation and transmission is highly plausible, we find that deprivation was not a significant driver of transmission heterogeneity during the vaccination rollout. The model accurately reproduces observed spatial and temporal variation in R t across England. To our knowledge, these findings provide the first population-level evidence that vaccination substantially reduces the SARS-CoV-2 reproduction number, supporting the UK’s “first-doses-first” prioritization as effective tools for epidemic control. More broadly, our modelling framework offers an approach for assessing transmission-blocking effects of vaccines against respiratory pathogens using routinely collected surveillance data, and has implications beyond SARS-CoV-2 for emerging threats such as avian influenza (H5N1).
- Open Access
Quantifying the impact of delaying the second COVID-19 vaccine dose in England: a mathematical modelling study
Background: The UK was the first country to start national COVID-19 vaccination programmes, initially administering doses 3-weeks apart. However, early evidence of high vaccine effectiveness after the first dose and the emergence of the Alpha variant prompted the UK to extend the interval between doses to 12-weeks. In this study, we quantify the impact of delaying the second vaccine dose on the epidemic in England. Methods: We used a previously described model of SARS-CoV-2 transmission and calibrated the model to English surveillance data including hospital admissions, hospital occupancy, seroprevalence data, and population-level PCR testing data using a Bayesian evidence synthesis framework. We modelled and compared the epidemic trajectory assuming that vaccine doses were administered 3-weeks apart against the real vaccine roll-out schedule. We estimated and compared the resulting number of daily infections, hospital admissions, and deaths. A range of scenarios spanning a range of vaccine effectiveness and waning assumptions were investigated. Findings: We estimate that delaying the interval between the first and second COVID-19 vaccine doses from 3- to 12-weeks prevented an average 64,000 COVID-19 hospital admissions and 9,400 deaths between 8 th December 2020 and 13th September 2021. Similarly, we estimate that the 3-week strategy would have resulted in more infections and deaths compared to the 12-week strategy. Across all sensitivity analyses the 3-week strategy resulted in a greater number of hospital admissions. Interpretation: England’s delayed second dose vaccination strategy was informed by early real-world vaccine effectiveness data and a careful assessment of the trade-offs in the context of limited vaccine supplies in a growing epidemic. Our study shows that rapidly providing partial vaccine-induced protection to a larger proportion of the population was successful in reducing the burden of COVID-19 hospitalisations and deaths. There is benefit in carefully considering and adapting guidelines in light of new emerging evidence and the population in question. Funding: National Institute for Health Research, UK Medical Research Council, Jameel Institute, Wellcome Trust, and UK Foreign, Commonwealth and Development Office, National Health and Medical Research Council. Research in Context: Evidence before this study: We searched PubMed up to 10 th June 2022, with no language restrictions using the following search terms: (COVID-19) AND (vaccin*) AND (dose OR dosing) AND (delay OR interval) AND (quant* OR assess* OR impact). We found 14 studies that explored the impact of different vaccine dosing intervals. However, the majority were prospective assessments of optimal vaccination strategies, exploring different trade-offs between vaccine mode of action, vaccine effectiveness, coverage, and availability. Only two studies retrospectively assessed the impact of different vaccination intervals. One assessed the optimal timing during the epidemic to switch to an extended dosing interval, and the other assessed the risk of all-cause mortality and hospitalisations between the two dosing groups. Added value of this study: Our data synthesis approach combines real-world evidence from multiple data sources to retrospectively quantify the impact of extending the COVID-19 vaccine dosing interval from the manufacturer recommended 3-weeks to 12-weeks in England. Implications of all the available evidence: Our study demonstrates that rapidly providing partial vaccine-induced protection to a larger proportion of the population was successful in reducing the COVID-19 hospitalisations and mortality. This was enabled by rapid and careful monitoring of vaccine effectiveness as nationwide vaccine programmes were initiated, and adaptation of guidelines in light of emerging evidence.
Open AccessQuantifying the impact of delaying the second COVID-19 vaccine dose in England: a mathematical modelling study
Background: The UK was the first country to start national COVID-19 vaccination programmes, initially administering doses 3-weeks apart. However, early evidence of high vaccine effectiveness after the first dose and the emergence of the Alpha variant prompted the UK to extend the interval between doses to 12-weeks. In this study, we quantify the impact of delaying the second vaccine dose on the epidemic in England. Methods: We used a previously described model of SARS-CoV-2 transmission and calibrated the model to English surveillance data including hospital admissions, hospital occupancy, seroprevalence data, and population-level PCR testing data using a Bayesian evidence synthesis framework. We modelled and compared the epidemic trajectory assuming that vaccine doses were administered 3-weeks apart against the real vaccine roll-out schedule. We estimated and compared the resulting number of daily infections, hospital admissions, and deaths. A range of scenarios spanning a range of vaccine effectiveness and waning assumptions were investigated. Findings: We estimate that delaying the interval between the first and second COVID-19 vaccine doses from 3- to 12-weeks prevented an average 64,000 COVID-19 hospital admissions and 9,400 deaths between 8 th December 2020 and 13th September 2021. Similarly, we estimate that the 3-week strategy would have resulted in more infections and deaths compared to the 12-week strategy. Across all sensitivity analyses the 3-week strategy resulted in a greater number of hospital admissions. Interpretation: England’s delayed second dose vaccination strategy was informed by early real-world vaccine effectiveness data and a careful assessment of the trade-offs in the context of limited vaccine supplies in a growing epidemic. Our study shows that rapidly providing partial vaccine-induced protection to a larger proportion of the population was successful in reducing the burden of COVID-19 hospitalisations and deaths. There is benefit in carefully considering and adapting guidelines in light of new emerging evidence and the population in question. Funding: National Institute for Health Research, UK Medical Research Council, Jameel Institute, Wellcome Trust, and UK Foreign, Commonwealth and Development Office, National Health and Medical Research Council. Research in Context: Evidence before this study: We searched PubMed up to 10 th June 2022, with no language restrictions using the following search terms: (COVID-19) AND (vaccin*) AND (dose OR dosing) AND (delay OR interval) AND (quant* OR assess* OR impact). We found 14 studies that explored the impact of different vaccine dosing intervals. However, the majority were prospective assessments of optimal vaccination strategies, exploring different trade-offs between vaccine mode of action, vaccine effectiveness, coverage, and availability. Only two studies retrospectively assessed the impact of different vaccination intervals. One assessed the optimal timing during the epidemic to switch to an extended dosing interval, and the other assessed the risk of all-cause mortality and hospitalisations between the two dosing groups. Added value of this study: Our data synthesis approach combines real-world evidence from multiple data sources to retrospectively quantify the impact of extending the COVID-19 vaccine dosing interval from the manufacturer recommended 3-weeks to 12-weeks in England. Implications of all the available evidence: Our study demonstrates that rapidly providing partial vaccine-induced protection to a larger proportion of the population was successful in reducing the COVID-19 hospitalisations and mortality. This was enabled by rapid and careful monitoring of vaccine effectiveness as nationwide vaccine programmes were initiated, and adaptation of guidelines in light of emerging evidence.
- Open Access
Prophylactic and reactive vaccination strategies for healthcare workers against MERS-CoV
Several vaccines candidates are in development against Middle East respiratory syndrome–related coronavirus (MERS-CoV), which remains a major public health concern. Using individual-level data on the 2013-2014 Kingdom of Saudi Arabia epidemic, we employ counterfactual analysis on inferred transmission trees (“who-infected-whom”) to assess potential vaccine impact. We investigate the conditions under which prophylactic “proactive” campaigns would outperform “reactive” campaigns (i.e. vaccinating either before or in response to the next outbreak), focussing on healthcare workers. Spatial scale is crucial: if vaccinating healthcare workers in response to outbreaks at their hospital only, proactive campaigns perform better, unless efficacy has waned significantly. However, campaigns that react at regional or national level consistently outperform proactive campaigns. Measures targeting the animal reservoir reduce transmission linearly, albeit with wide uncertainty. Substantial reduction of MERS-CoV morbidity and mortality is possible when vaccinating healthcare workers, underlining the need for at-risk countries to stockpile vaccines when available.
Open AccessProphylactic and reactive vaccination strategies for healthcare workers against MERS-CoV
Several vaccines candidates are in development against Middle East respiratory syndrome–related coronavirus (MERS-CoV), which remains a major public health concern. Using individual-level data on the 2013-2014 Kingdom of Saudi Arabia epidemic, we employ counterfactual analysis on inferred transmission trees (“who-infected-whom”) to assess potential vaccine impact. We investigate the conditions under which prophylactic “proactive” campaigns would outperform “reactive” campaigns (i.e. vaccinating either before or in response to the next outbreak), focussing on healthcare workers. Spatial scale is crucial: if vaccinating healthcare workers in response to outbreaks at their hospital only, proactive campaigns perform better, unless efficacy has waned significantly. However, campaigns that react at regional or national level consistently outperform proactive campaigns. Measures targeting the animal reservoir reduce transmission linearly, albeit with wide uncertainty. Substantial reduction of MERS-CoV morbidity and mortality is possible when vaccinating healthcare workers, underlining the need for at-risk countries to stockpile vaccines when available.
- Open Access
- 14 July 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (602)
Key epidemiological drivers and impact of interventions in the 2020 SARS-CoV-2 epidemic in England
We fitted a model of SARS-CoV-2 transmission in care homes and the community to regional surveillance data for England. Compared with other approaches, our model provides a synthesis of multiple surveillance data streams into a single coherent modelling framework allowing transmission and severity to be disentangled from features of the surveillance system. Of the control measures implemented, only national lockdown brought the reproduction number (Rteff) below 1 consistently; if introduced one week earlier it could have reduced deaths in the first wave from an estimated 48,600 to 25,600 (95% credible interval [95%CrI]: 15,900–38,400). The infection fatality ratio decreased from 1.00% (95%CrI: 0.85%–1.21%) to 0.79% (95%CrI: 0.63%–0.99%), suggesting improved clinical care. The infection fatality ratio was higher in the elderly residing in care homes (23.3%, 95%CrI: 14.7%–35.2%) than those residing in the community (7.9%, 95%CrI: 5.9%–10.3%). On 2nd December 2020 England was still far from herd immunity, with regional cumulative infection incidence between 7.6% (95%CrI: 5.4%–10.2%) and 22.3% (95%CrI: 19.4%–25.4%) of the population. Therefore, any vaccination campaign will need to achieve high coverage and a high degree of protection in vaccinated individuals to allow non-pharmaceutical interventions to be lifted without a resurgence of transmission.
- 14 July 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (602)
Open AccessKey epidemiological drivers and impact of interventions in the 2020 SARS-CoV-2 epidemic in England
We fitted a model of SARS-CoV-2 transmission in care homes and the community to regional surveillance data for England. Compared with other approaches, our model provides a synthesis of multiple surveillance data streams into a single coherent modelling framework allowing transmission and severity to be disentangled from features of the surveillance system. Of the control measures implemented, only national lockdown brought the reproduction number (Rteff) below 1 consistently; if introduced one week earlier it could have reduced deaths in the first wave from an estimated 48,600 to 25,600 (95% credible interval [95%CrI]: 15,900–38,400). The infection fatality ratio decreased from 1.00% (95%CrI: 0.85%–1.21%) to 0.79% (95%CrI: 0.63%–0.99%), suggesting improved clinical care. The infection fatality ratio was higher in the elderly residing in care homes (23.3%, 95%CrI: 14.7%–35.2%) than those residing in the community (7.9%, 95%CrI: 5.9%–10.3%). On 2nd December 2020 England was still far from herd immunity, with regional cumulative infection incidence between 7.6% (95%CrI: 5.4%–10.2%) and 22.3% (95%CrI: 19.4%–25.4%) of the population. Therefore, any vaccination campaign will need to achieve high coverage and a high degree of protection in vaccinated individuals to allow non-pharmaceutical interventions to be lifted without a resurgence of transmission.
- Open Access
Modelling the impact of the tier system on SARS-CoV-2 transmission in the UK between the first and second national lockdowns
Objective: To measure the effects of the tier system on the COVID-19 pandemic in the UK between the first and second national lockdowns, before the emergence of the B.1.1.7 variant of concern. Design: This is a modelling study combining estimates of real-time reproduction number R t (derived from UK case, death and serological survey data) with publicly available data on regional non-pharmaceutical interventions. We fit a Bayesian hierarchical model with latent factors using these quantities to account for broader national trends in addition to subnational effects from tiers. Setting: The UK at lower tier local authority (LTLA) level. 310 LTLAs were included in the analysis. Primary and secondary outcome measures: Reduction in real-time reproduction number R t . Results: Nationally, transmission increased between July and late September, regional differences notwithstanding. Immediately prior to the introduction of the tier system, R t averaged 1.3 (0.9–1.6) across LTLAs, but declined to an average of 1.1 (0.86–1.42) 2 weeks later. Decline in transmission was not solely attributable to tiers. Tier 1 had negligible effects. Tiers 2 and 3, respectively, reduced transmission by 6% (5%–7%) and 23% (21%–25%). 288 LTLAs (93%) would have begun to suppress their epidemics if every LTLA had gone into tier 3 by the second national lockdown, whereas only 90 (29%) did so in reality. Conclusions: The relatively small effect sizes found in this analysis demonstrate that interventions at least as stringent as tier 3 are required to suppress transmission, especially considering more transmissible variants, at least until effective vaccination is widespread or much greater population immunity has amassed.
Open AccessModelling the impact of the tier system on SARS-CoV-2 transmission in the UK between the first and second national lockdowns
Objective: To measure the effects of the tier system on the COVID-19 pandemic in the UK between the first and second national lockdowns, before the emergence of the B.1.1.7 variant of concern. Design: This is a modelling study combining estimates of real-time reproduction number R t (derived from UK case, death and serological survey data) with publicly available data on regional non-pharmaceutical interventions. We fit a Bayesian hierarchical model with latent factors using these quantities to account for broader national trends in addition to subnational effects from tiers. Setting: The UK at lower tier local authority (LTLA) level. 310 LTLAs were included in the analysis. Primary and secondary outcome measures: Reduction in real-time reproduction number R t . Results: Nationally, transmission increased between July and late September, regional differences notwithstanding. Immediately prior to the introduction of the tier system, R t averaged 1.3 (0.9–1.6) across LTLAs, but declined to an average of 1.1 (0.86–1.42) 2 weeks later. Decline in transmission was not solely attributable to tiers. Tier 1 had negligible effects. Tiers 2 and 3, respectively, reduced transmission by 6% (5%–7%) and 23% (21%–25%). 288 LTLAs (93%) would have begun to suppress their epidemics if every LTLA had gone into tier 3 by the second national lockdown, whereas only 90 (29%) did so in reality. Conclusions: The relatively small effect sizes found in this analysis demonstrate that interventions at least as stringent as tier 3 are required to suppress transmission, especially considering more transmissible variants, at least until effective vaccination is widespread or much greater population immunity has amassed.
- Top Cited PapersOpen Access
- 24 July 2020
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 369 (6502) , 413-422
The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries
Global prospects for COVID-19 control: Lower-income countries have recognized the potential impact of coronavirus disease 2019 (COVID-19) from observing ongoing epidemics. Many have intervened quickly and early with measures to slow viral transmission, which may partly explain the low rates observed so far in these countries. Walker et al. calibrated a global model with country-specific data (see the Perspective by Metcalf et al. ). Despite the potentially protective effects of younger demographics, the closer intergenerational contact, limitations on health care facilities, and frequency of comorbidities in lower-income countries require sustained nonpharmaceutical interventions (NPIs) to avoid overwhelming health care capacity. As a result of strict NPIs, the protective effects of immunity will be reduced, and it will be important to improve testing capacity. Ensuring equitable provision of oxygen and—when they are ready—pharmaceutical interventions should be a global priority. Science , this issue p. 413 ; see also p. 368
- 24 July 2020
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 369 (6502) , 413-422
Top Cited PapersOpen AccessThe impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries
Global prospects for COVID-19 control: Lower-income countries have recognized the potential impact of coronavirus disease 2019 (COVID-19) from observing ongoing epidemics. Many have intervened quickly and early with measures to slow viral transmission, which may partly explain the low rates observed so far in these countries. Walker et al. calibrated a global model with country-specific data (see the Perspective by Metcalf et al. ). Despite the potentially protective effects of younger demographics, the closer intergenerational contact, limitations on health care facilities, and frequency of comorbidities in lower-income countries require sustained nonpharmaceutical interventions (NPIs) to avoid overwhelming health care capacity. As a result of strict NPIs, the protective effects of immunity will be reduced, and it will be important to improve testing capacity. Ensuring equitable provision of oxygen and—when they are ready—pharmaceutical interventions should be a global priority. Science , this issue p. 413 ; see also p. 368